Pandemic Darlings The pandemic economy, in original documents
Home Form 4: Arcturus Therapeutics Holdings Inc. (ARCT), Sassine Andy, transaction 06/10/2020Search ⌕

Form 4: Arcturus Therapeutics Holdings Inc. (ARCT), Sassine Andy, transaction 06/10/2020

Summary

Form 4 for Arcturus Therapeutics Holdings Inc. reporting a June 10, 2020 transaction by SASSINE ANDY, listed as a director and Chief Financial Officer. Table I shows 5,000 shares of Common Stock acquired under transaction code P at $29.74 per share. After the transaction the reporting person beneficially owns 273,245 shares directly. Ilan Katz signed as attorney-in-fact the same day, June 10, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Form 4: Arcturus Therapeutics Holdings Inc. (ARCT), Sassine Andy, transaction 06/10/2020.” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-arct-4-filed2020-06-10-0000899243-20-016049-f0385675de/, SHA-256 82f2b3e1b25640cc6198a70bd499f1da9048d04bc0ec15b77484c77918ff880b.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * SASSINE ANDY (Last) (First) (Middle) C/O ARCTURUS THERAPEUTICS HOLDINGS INC. 10628 SCIENCE CENTER DRIVE, SUITE 250 (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | SASSINE ANDY | (Last) | (First) | (Middle) | C/O ARCTURUS THERAPEUTICS HOLDINGS INC. | 10628 SCIENCE CENTER DRIVE, SUITE 250 | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Arcturus Therapeutics Holdings Inc. [ ARCT ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Financial Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 06/10/2020
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 06/10/2020 | P | 5,000 | A | $ 29.74 | 273,245 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Ilan Katz, attorney-in-fact | 06/10/2020
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_ARCT_4_filed2020-06-10_0000899243-20-016049.xml
Size
14,917 bytes
SHA-256
82f2b3e1b25640cc6198a70bd499f1da9048d04bc0ec15b77484c77918ff880b
Our copy
SEC_ARCT_4_filed2020-06-10_0000899243-20-016049.xml
Original
www.sec.gov
Back to top